Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CHMP Adopts Negative Opinion On KYNAMROTM - Quick Facts

Genzyme, a Sanofi company (SNY: Quote), and Isis Pharmaceuticals Inc. (ISIS: Quote), announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a negative opinion for its marketing authorization application for KYNAMROTM for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Genzyme plans to request a re-examination of the CHMP Opinion.

An application for KYNAMRO is currently under review by the U.S. FDA.

Click here to receive FREE breaking news email alerts for Genzyme Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply lower at the open, stocks showed a substantial recovery attempt over the course of the trading day on Monday. The Nasdaq and the S&P 500 bounced well off the one-month intraday lows set in early trading but still closed in the red. While most Americans oppose sending ground troops into combat operations against the terrorist group known as ISIS, the results of a CNN/ORC International poll found that an even larger majority think the American military will still end up putting boots on the ground. With incumbent Sen. Kay Hagan, D-N.C., and Republican challenger Thom Tillis running nearly neck-and-neck in the North Carolina Senate race, the results of a new CNN/ORC International survey suggest that the race could be decided by the number of votes for Libertarian candidate Sean Haugh.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.